A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer

被引：1
|
作者：
Robertson, J. F. R.
Zefei, J.
Di Leo, A.
Ohno, S.
Pritchard, K. I.
Ellis, M.
Bradbury, I.
Campbell, C.
机构：
[1] Univ Nottingham, Div Breast Surg, Nottingham NG7 2RD, England
[2] Chinese Peoples Liberat Army, Hosp 307, Beijing, Peoples R China
[3] Hosp Prato, Sandro Pitigliani Med Oncol Unit, Prato, Italy
[4] Canc Inst Hosp, Breast Oncol Ctr, Tokyo, Japan
[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Univ Toronto, Toronto, ON, Canada
[7] Baylor Coll Med, Houston, TX 77030 USA
[8] Frontier Sci, Kingussie, Inverness, Scotland
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P5-14-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-14-01
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials
    Graham, Jeffrey
    Pitz, Marshall
    Gordon, Vallerie
    Grenier, Debjani
    Amir, Eitan
    Niraula, Saroj
    CANCER TREATMENT REVIEWS, 2016, 45 : 1 - 6
  • [42] Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer
    Ding, H.
    Fang, L.
    Xin, W.
    Tong, Y.
    Zhou, Q.
    Huang, P.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [43] A Phase II Study (FINDER 2) Comparing Three Dosing Regimens of Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer
    Pritchard, K., I
    Rolski, J.
    Papai, Z.
    Mauriac, L.
    Cardoso, F.
    Fukase, K.
    Lindemann, J. P. O.
    Macpherson, M. P.
    Neven, P.
    CANCER RESEARCH, 2009, 69 (24) : 738S - 738S
  • [44] Clinical predictors of benefit from fulvestrant in advanced breast cancer: A meta-analysis of randomized controlled trials
    Niraula, S.
    Pitz, M.
    Gordon, V.
    Grenier, D.
    Amir, E.
    Brandes, L.
    CANCER RESEARCH, 2016, 76
  • [45] Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer
    Chia, Stephen
    Gradishar, William
    BREAST, 2008, 17 : S16 - S21
  • [46] Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
    Spring, Laura M.
    Gupta, Arjun
    Reynolds, Kerry L.
    Gadd, Michele A.
    Ellisen, Leif W.
    Isakoff, Steven J.
    Moy, Beverly
    Bardia, Aditya
    JAMA ONCOLOGY, 2016, 2 (11) : 1477 - 1486
  • [47] Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer
    McCormack, Peter
    Sapunar, Francisco
    CLINICAL BREAST CANCER, 2008, 8 (04) : 347 - 351
  • [48] Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada
    Djalalov, S.
    Beca, J.
    Amir, E.
    Krahn, M.
    Trudeau, M. E.
    Hoch, J. S.
    CURRENT ONCOLOGY, 2015, 22 (02) : 84 - 96
  • [49] NEWEST: a Phase II, randomised, neoadjuvant trial comparing fulvestrant 500 mg vs 250 mg in postmenopausal women with locally advanced, oestrogen receptor-positive (ER+) breast cancer
    Singer, C.
    Kuter, I.
    Hegg, R.
    Badwe, R.
    Harbeck, N.
    Bines, J.
    Lowe, E.
    EJC SUPPLEMENTS, 2008, 6 (07): : 115 - 115
  • [50] Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant
    Calhoun, KE
    Pommier, RF
    Muller, P
    Fletcher, WS
    Toth-Fejel, S
    ARCHIVES OF SURGERY, 2003, 138 (08) : 879 - 882
12345